Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Item
http://www.wikidata.org/entity/Q37873164
Marine Natural Products as Models to Circumvent Multidrug ResistanceTumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.Bevacizumab in the treatment of metastatic breast cancer: friend or foe?Recent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsProteomics of cancer cell lines resistant to microtubule-stabilizing agents.Novel molecular targets for the therapy of urothelial carcinoma.Novel and highly potent antitumour natural products from cnidarians of marine origin.Anticancer agent-based marine natural products and related compounds.Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines.Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.Axonal Transport Impairment in Chemotherapy-Induced Peripheral NeuropathyEffects of Paclitaxel and Eribulin in Mouse Sciatic Nerve: A Microtubule-Based Rationale for the Differential Induction of Chemotherapy-Induced Peripheral Neuropathy.Microtubule-Targeting Agents Eribulin and Paclitaxel Differentially Affect Neuronal Cell Bodies in Chemotherapy-Induced Peripheral Neuropathy.A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
P2860

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Item
http://www.wikidata.org/entity/Q37873164
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
@en
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
@nl
type
label
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
@en
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
@nl
prefLabel
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
@en
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
@en
P2093
P304
P31
P356
10.1016/J.CTRV.2011.03.006
P433
P478
P50
P577
P5875
P698
P921